BIOCRYST PHARMACEUTICALS, INC. (BCRX) Operating cash flow 2016–2025
BIOCRYST PHARMACEUTICALS, INC. (BCRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$347.4MFY2025 · since FY2016: -$53.4M → $347.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $347.4M | +767.8% |
| FY2024 | -$52.0M | +45.3% |
| FY2023 | -$95.1M | +41.2% |
| FY2022 | -$161.8M | -13.9% |
| FY2021 | -$142.2M | -5.2% |
| FY2020 | -$135.1M | -50.8% |
| FY2019 | -$89.6M | +3.2% |
| FY2018 | -$92.6M | -125.0% |
| FY2017 | -$41.1M | +23.0% |
| FY2016 | -$53.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Net marginBCRX Gross profitBCRX Gross marginBCRX Operating incomeBCRX Operating marginBCRX Free cash flowBCRX Capital expendituresBCRX Return on equityBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Total liabilitiesBCRX Shareholders’ equityBCRX overview →